238 related articles for article (PubMed ID: 9420203)
1. Protective efficacy of DNA vaccines against duck hepatitis B virus infection.
Triyatni M; Jilbert AR; Qiao M; Miller DS; Burrell CJ
J Virol; 1998 Jan; 72(1):84-94. PubMed ID: 9420203
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
Miller DS; Halpern M; Kotlarski I; Jilbert AR
Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
Miller DS; Kotlarski I; Jilbert AR
Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364
[TBL] [Abstract][Full Text] [Related]
4. Protective and therapeutic effect of DNA-based immunization against hepadnavirus large envelope protein.
Rollier C; Sunyach C; Barraud L; Madani N; Jamard C; Trepo C; Cova L
Gastroenterology; 1999 Mar; 116(3):658-65. PubMed ID: 10029625
[TBL] [Abstract][Full Text] [Related]
5. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
6. In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.
Saade F; Buronfosse T; Guerret S; Pradat P; Chevallier M; Zoulim F; Jamard C; Cova L
J Viral Hepat; 2013 Apr; 20(4):e56-65. PubMed ID: 23490390
[TBL] [Abstract][Full Text] [Related]
7. In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins.
Khawaja G; Buronfosse T; Jamard C; Abdul F; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans CF; Hartmann D; Cova L
Virology; 2012 Nov; 433(1):192-202. PubMed ID: 22921316
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the kinetics of the specific cellular immune response to duck hepatitis B virus in infected and immune ducks.
Vickery K; Cossart Y; Dixon R
Vet Microbiol; 1999 Aug; 68(1-2):157-69. PubMed ID: 10501173
[TBL] [Abstract][Full Text] [Related]
9. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo.
Nicoll A; Locarnini S; Chou ST; Smallwood R; Angus P
J Gastroenterol Hepatol; 2000 Mar; 15(3):304-10. PubMed ID: 10764033
[TBL] [Abstract][Full Text] [Related]
10. Duck hepatitis B virus (DHBV) infection in Indian domestic ducks: a pilot study.
Sridhar G; Valliammai T; Varalakshmi CS; Udayasankar K; Panchanadam M; Ramakrishna J; Gopal KV; Jayaraman K; Thyagarajan SP
Trop Anim Health Prod; 1993 Nov; 25(4):229-33. PubMed ID: 8109057
[TBL] [Abstract][Full Text] [Related]
11. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
12. Characterization of age- and dose-related outcomes of duck hepatitis B virus infection.
Jilbert AR; Botten JA; Miller DS; Bertram EM; Hall PM; Kotlarski J; Burrell CJ
Virology; 1998 May; 244(2):273-82. PubMed ID: 9601498
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes.
Saade F; Buronfosse T; Pradat P; Abdul F; Cova L
Vaccine; 2008 Sep; 26(40):5159-64. PubMed ID: 18554756
[TBL] [Abstract][Full Text] [Related]
14. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.
Thermet A; Buronfosse T; Werle-Lapostolle B; Chevallier M; Pradat P; Trepo C; Zoulim F; Cova L
J Gen Virol; 2008 May; 89(Pt 5):1192-1201. PubMed ID: 18420797
[TBL] [Abstract][Full Text] [Related]
15. Recombinant vaccinia virus expressing Pre-S/S protein of duck hepatitis B virus and its preliminary use for treatment of persistent infection.
Ma ZM; Kong YY; Wang Y; Wen YM
Acta Virol; 1996; 40(5-6):311-4. PubMed ID: 9171461
[TBL] [Abstract][Full Text] [Related]
16. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
[TBL] [Abstract][Full Text] [Related]
17. Viral load in 1-day-old ducklings acutely infected with duck hepatitis B virus by different doses and routes of inoculation.
Chen ZY; Cheng AC; Wang MS; Xu DW; Jia R; Guo YF; Zeng W
Avian Pathol; 2009 Apr; 38(2):129-34. PubMed ID: 19322711
[TBL] [Abstract][Full Text] [Related]
18. IFN-gamma increases efficiency of DNA vaccine in protecting ducks against infection.
Long JE; Huang LN; Qin ZQ; Wang WY; Qu D
World J Gastroenterol; 2005 Aug; 11(32):4967-73. PubMed ID: 16124047
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks.
Jilbert AR; Miller DS; Scougall CA; Turnbull H; Burrell CJ
Virology; 1996 Dec; 226(2):338-45. PubMed ID: 8955053
[TBL] [Abstract][Full Text] [Related]
20. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
